关键词：后天；孤儿血液疾病；骨髓的无能；血小板减少；贫血；血栓形成；非遗传性疾病
摘 要：Acquired orphan blood diseases are characterized by the inability of the bone marrow to produce sufficient amount of RBCs resulting in decreased platelet count, anemia, and thrombosis. They are rare and non-genetic diseases originating after the development of the fetus. ITP, MDS, MF PNH, and PV are major acquired orphan blood diseases. The detailed overview of thee diseases including their management are discussed further in this report.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1 Soliris

04.2 Nplate

04.3 Revlimid

04.4 Vidaza

04.5 Promacta

04.6 Jakafi

04.7 Rituxan

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Diseases Overview

07.1 ITP

07.1.1 Understanding the Disease

07.1.2 Epidemiology

07.1.3 Etiology

07.1.4 Pathophysiology

07.1.5 Management of Disease

07.2 MDS

07.2.1 Understanding the Disease

07.2.2 Epidemiology

07.2.3 Etiology

07.2.4 Pathophysiology

07.2.5 Management of Disease

07.3 MF

07.3.1 Understanding the Disease

07.3.2 Epidemiology

07.3.3 Etiology

07.3.4 Pathophysiology

07.3.5 Management of Disease

07.4 PNH

07.4.1 Understanding the Disease

07.4.2 Epidemiology

07.4.3 Etiology

07.4.4 Pathophysiology

07.4.5 Management of Disease

07.5 PV

07.5.1 Understanding the Disease

07.5.2 Epidemiology

07.5.3 Etiology

07.5.4 Pathophysiology

07.5.5 Management of Disease

07.6 Pipeline Analysis

07.7 Emerging Treatment Options

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Five Forces Analysis

09. Market Segmentation by Indication Type

09.1 Global ITP Therapeutics Market

09.1.1 Market Size and Forecast

09.2 Global MDS Therapeutics Market

09.2.1 Market Size and Forecast

09.3 Global MF Therapeutics Market

09.3.1 Market Size and Forecast

09.4 Global PNH Therapeutics Market

09.4.1 Market Size and Forecast

09.5 Global PV Therapeutics Market

09.5.1 Market Size and Forecast

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2014

18.2.1 Competitive Assessment of Top Drugs

18.2.2 F. Hoffmann-La Roche

18.2.3 Celgene

18.2.4 Alexion Pharmaceuticals

18.2.5 Amgen

18.2.6 Incyte

18.2.7 GlaxoSmithKline

18.3 Other Prominent Vendors

19. Key Vendor Analysis

19.1 Amgen

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Business Segmentation by Revenue 2013

19.1.4 Product Portfolio by Revenue 2013

19.1.5 Business Segmentation by Revenue 2012 and 2013

19.1.6 Geographical Segmentation by Revenue 2013

19.1.7 Business Strategy

19.1.8 Recent Developments

19.1.9 SWOT Analysis

19.2 Alexion

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Geographical Segmentation by Revenue 2013

19.2.4 Business Strategy

19.2.5 Recent Developments

19.2.6 SWOT Analysis

19.3 Celgene

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Business Strategy

19.3.4 Business Segmentation by Revenue

19.3.5 Sales by Geography

19.3.6 Key Information

19.3.7 SWOT Analysis

19.4 F. Hoffmann-La Roche Ltd.

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation

19.4.4 Business Segmentation by Revenue 2012 and 2013

19.4.5 Sales by Geography

19.4.6 Business Strategy

19.4.7 Key Information

19.4.8 SWOT Analysis

19.5 GlaxoSmithKline

19.5.1 Key Facts

19.5.2 Business Overview

19.5.3 Business Segmentation

19.5.4 Business Segmentation by Revenue 2012 and 2013

19.5.5 Sales by Geography

19.5.6 Pipeline Products

19.5.7 Business Strategy

19.5.8 Key Information

19.5.9 SWOT Analysis

19.5.10 Strengths

19.5.11 Weaknesses

19.5.12 Opportunities

19.5.13 Threats

19.6 Incyte

19.6.1 Key Facts

19.6.2 Business Overview

19.6.3 Revenue Segmentation by 2013

19.6.4 Revenue Segmentation by 2012 and 2013

19.6.5 Geographical Segmentation

19.6.6 Business Strategy

19.6.7 Recent Developments .

19.6.8 SWOT Analysis

20. Other Reports in this Series